Our research and clinical trials have made us a leader in improving survival rates for hard-to-treat pediatric brain tumors like medulloblastoma and atypical teratoid rhabdoid tumor (ATRT). We also were the first pediatric hospital to install a mobile “intraoperative MRI,” which allows surgeons to obtain images while the patient is still under anesthesia and to perform further procedures as needed.
This is a two arm Phase I study within the Pacific Pediatric Neuro-Oncology Consortium (PNOC) that looks to determine the safety and recommended phase 2 dose of the modified measles virus (MV-NIS) in children and young adults with recurrent medulloblastoma or atypical teratoid rhabdoid tumor (ATRT). For locally recurrent patients, MV-NIS will be directly administered into the tumor bed following a standard of care surgical resection. For patients with disseminated recurrence, MV-NIS will be injected via lumbar puncture (LP). Patients will be closely monitored for 30 days after injection, and then followed for evaluation of six months progressive free survival and overall response rate.
PI: Susan N. Chi, MD
Search for pediatric brain tumor clinical trials by condition using the links below.